TAUSEEF AHMED
Medical Practice in Briarcliff, NY

License number
Michigan 4301040644
Issued Date
Mar 20, 1979
Expiration Date
Jan 31, 2010
Category
Medicine
Type
Medical Doctor
Address
Address
Briarcliff, NY 10510

Professional information

Tauseef Ahmed Photo 1

Taxane Analogs For The Treatment Of Brain Cancer

US Patent:
8409574, Apr 2, 2013
Filed:
Aug 20, 2010
Appl. No.:
12/859990
Inventors:
James D. McChesney - Etta MS, US
Gilles Tapolsky - Boulder CO, US
David E. Emerson - Longmont CO, US
John Marshall - Washington DC, US
Tauseef Ahmed - Briarcliff Manor NY, US
Allen Cohn - Englewood CO, US
Michael Kurman - Upper Saddle River NJ, US
Manuel Modiano - Tucson AZ, US
International Classification:
A61K 39/00, A61K 31/415, A61K 31/335, A01N 43/52, A01N 43/32, C07D 309/00
US Classification:
4241331, 514393, 514452, 549358
Abstract:
Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.


Tauseef Ahmed Photo 2

Taxane Analogs For The Treatment Of Brain Cancer

US Patent:
2013025, Sep 26, 2013
Filed:
Mar 5, 2013
Appl. No.:
13/785753
Inventors:
Gilles Tapolsky - Louisville KY, US
David E. Emerson - Longmont CO, US
John Marshall - Washington DC, US
Tauseef Ahmed - Briarcliff Manor NY, US
Allen Cohn - Englewood CO, US
Michael Kurman - Upper Saddle River NJ, US
Manuel Modiano - Tucson AZ, US
International Classification:
A61K 31/357
US Classification:
514452, 549358
Abstract:
Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.